Sareum Holdings Temettü

Temettü kriter kontrolleri 0/6

Sareum Holdings şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.4%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-UK£0.027
Gelecekteki Temettü Verimi	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation

Aug 24

What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Dec 23

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SAR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SAR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Sareum Holdings Piyasaya Karşı Temettü Getirisi

SAR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SAR)	n/a
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.8%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (SAR) (3 yıla kadar)	0%

Önemli Temettü: SAR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SAR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SAR şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SAR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Sareum Holdings Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

Sareum Holdings plc to Report Fiscal Year 2024 Results on Oct 29, 2024

Sareum Holdings plc has completed a Follow-on Equity Offering in the amount of £1 million.

New minor risk - Financial data availability

Sareum Holdings plc Receives Notice of Allowance from the China National Intellectual Property Administration

Sareum Holdings plc Receives A Notice of Allowance from the US Patent and Trademark Office for A Patent on SDC-1801

Sareum Holdings plc Announces Transition of Chief Executive Officer

Sareum Holdings plc Announces Positive Data from SDC-1801 Phase 1 Clinical Trial

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Sareum Holdings plc has completed a Follow-on Equity Offering in the amount of £1.268973 million.

Sareum Holdings plc has filed a Follow-on Equity Offering in the amount of £0.1875 million.

New major risk - Market cap size

Forecast to breakeven in 2026

New major risk - Share price stability

Sareum Holdings plc Announces Completion of the Single Ascending Dose (SAD) Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801

Sareum Holdings plc Provides Update on Operational Activities and Pipeline Progress

Sareum Holdings plc, Annual General Meeting, Dec 14, 2023

Sareum Holdings plc Initiates Food Effects Study in Phase 1a Trial for SDC-1801

New minor risk - Insider selling

New minor risk - Shareholder dilution

New minor risk - Financial data availability

Sareum Holdings plc to Report Fiscal Year 2023 Results on Oct 09, 2023

Sareum Holdings plc Starts Dosing First Subjects in the Multiple Ascending Dose Part of Phase 1a Clinical Trial for SDC-1801

Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation

Sareum Holdings plc Provides Earnings Guidance for the Year to 30 June 2023

New major risk - Share price stability

New minor risk - Market cap size

Sareum Holdings plc Announces the Commencement of A Phase 1a Clinical Trial for SDC-1801

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Sareum Holdings plc, Annual General Meeting, Dec 16, 2022

Sareum Holdings plc Notes Publication of SRA737 Clinical Data

Insufficient new directors

Sareum Holdings plc Notes FDA Approval of First TYK2 Inhibitor

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Sareum Submits Clinical Trial Authorisation Application to UK MHRA for Development of TYK2/JAK1 Inhibitor SDC-1801

Sareum Holdings plc Provides Consolidated Sales Guidance for the Fiscal Year 2022

Insufficient new directors

We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth

Sareum Holdings plc Announces European Patent Granted for Sareum’s SDC-1802

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Insufficient new directors

Founder exercised options and sold UK£123k worth of stock

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Sareum Holdings plc Provides Financial Guidance for Fiscal 2021

We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely

Sareum Holdings plc Launched of Its AGILE Clinical Development Platform to Fund Phase 1 Trials and Fast-Track the Development of Potentially Ground-Breaking COVID-19 Treatments

Sareum Holdings plc Provides Update on FLT3+Aurora Kinase Inhibitor Programme

What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Sareum Holdings plc Announces TYK2 as Key Causative Genetic Mechanism and Potential Target for Therapy

Sareum Holdings plc, Annual General Meeting, Dec 15, 2020

Sareum Holdings plc Announces That US Patent Allowance for Sareum's SDC-1802 TYK2/JAK1 Inhibitor

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin